News

Doping for UK's biomedicine
Enlarge image

BusinessUK

Doping for UK's biomedicine

03.08.2012 - The UK government has pledged to invest additional €49m (£39m) in the country's life science research.

The Biomedical Catalyst Fund commited €12,6m (£10m) to 14 universities and 18 small- and medium-sized enterprises (SMEs) to explore the market potential of early-stage ideas. Each of the universities received up to £750k, while each company received up to £150k to propel their projects. These are the first investments for the three-year, €227m (£180m) fund. It is part of the Strategy for Life Science unveiled by UK’s Prime Minister David Cameron December last year to foster the domestic life science industry. The grants will fund about 150 pilot projects, allowing academic researchers to begin the process of turning a bright idea into a viable proposition. Universities have control over allocating the funding internally, allowing them to respond rapidly to new opportunities and have the flexibility to pursue the most promising translational research opportunities.

In an effort to establish four e-health centres of excellence in London, Manchester, Dundee and Swansea, UK’s Medical Research Council has teamed up with a consortium of ten public and charity research funders. The centres will focus on conditions including cancer, diabetes, obesity and cardiovascular disease. The researchers working at these centers will link information in NHS health records with other forms of research and routinely-collected data to improve patient care and public health.

Only days ago, Cameron unveiled plans to converse the Olympic drug testing laboratories located in Harlow into a phenome research centre after the Games are complete. The concept of the phenome encapsulates all of an individual’s traits, which are the outcome of a continuous interplay between their genes and the environment. It will be funded by €12,6m (£10m) investments over five years by both the Medical Research Council and the Department of Health’s National Institute for Health Research. Two companies who make scientific instruments - Bruker, and Waters Corporation – will invest additional €25,2m (£20m). Imperial College and King’s College London will be academic partners in the project.

http://www.european-biotechnology-news.com/news/news/2012-03/doping-for-uks-biomedicine.html

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.28 EUR10.34%
  • BASILEA110.70 CHF2.31%
  • BIOTEST98.10 EUR2.29%

FLOP

  • PAION2.36 EUR-6.72%
  • MOLOGEN5.45 EUR-4.22%
  • WILEX3.01 EUR-2.90%

TOP

  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.31 EUR189.6%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS58.81 EUR-21.3%
  • WILEX3.01 EUR-12.2%
  • BASILEA110.70 CHF-9.4%

TOP

  • SANTHERA93.75 CHF2214.8%
  • FORMYCON26.94 EUR271.6%
  • WILEX3.01 EUR220.2%

FLOP

  • CYTOS1.43 CHF-52.3%
  • MOLOGEN5.45 EUR-52.0%
  • PAION2.36 EUR-35.0%

No liability assumed, Date: 31.03.2015